| EGRX Shares Outstanding History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the EGRX shares outstanding history going back to 2/12/2014:
Also see: EGRX Market Cap History EGRX YTD Return |
EGRX Shares Outstanding History — Eagle Pharmaceuticals Share Count Over Time
As of 8/1/2023 Eagle Pharmaceuticals has 12.99 million EGRX shares outstanding. Investors often track the EGRX shares outstanding history to compare shareholder return trends against the change in share count over time.
This page shows EGRX share count trends over time, with 41 historical shares outstanding datapoints presented, dating back to 2/12/2014.
| EGRX Shares Outstanding History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EGRX Historical Shares Outstanding: -0.72% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EGRX Stock Price Chart |
| About Eagle Pharmaceuticals, Inc. |
| Eagle Pharmaceuticals is an integrated pharmaceutical company with research and development, clinical, manufacturing and commercial capabilities. Co.'s products and product portfolio include: BARHEMSYS® (amisulpride for injection), which is for the treatment of postoperative nausea and vomiting; BYFAVO® (remimazolam for injection), which is indicated for the induction and maintenance of procedural sedation; bendamustine ready-to-dilute (RTD) 500ml solution, infused bendamustine RTD, and bendamustine RTD and infused RTD in Japan for Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma; Ryanodex® (dantrolene sodium) for Malignant Hyperthermia; and EA-114 (fulvestrant) for breast cancer. We show 41 historical shares outstanding datapoints in our coverage of EGRX's shares outstanding history. Understanding the changing numbers of EGRX shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like EGRX versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching EGRX by allowing them to research EGRX shares outstanding history as well as any other stock in our coverage universe. |
| EGRX Current Stock Quote |
Quotes delayed 20 minutes  Free EGRX Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: Shares Outstanding Importance | |
|
Video: Shares Outstanding Importance
| EGRX Share Performance |
| Shares Outstanding Peers |
| Eagle Pharmaceuticals (EGRX) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:
EHAB Shares Outstanding History EHC Shares Outstanding History EIDX Shares Outstanding History EIGR Shares Outstanding History EKSO Shares Outstanding History ELAB Shares Outstanding History ELAN Shares Outstanding History ELDN Shares Outstanding History ELEV Shares Outstanding History ELGX Shares Outstanding History More Healthcare companies » |
EGRX Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
